Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KPE 02001003

Drug Profile

KPE 02001003

Alternative Names: KPE02001003; KPE02003002

Latest Information Update: 18 Dec 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kemin Pharma; National Institutes of Health (USA); Rega Institute for Medical Research
  • Developer Kemin Pharma
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 18 Dec 2008 No development reported - Phase-II for Hepatitis C in Belgium (unspecified route)
  • 13 Jan 2005 KPE 02001003 is available for licensing worldwide (http://www.kemin.com)
  • 15 Jan 2004 Phase-II clinical trials in Hepatitis C treatment in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top